美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Obsidian Therapeutics Inc

19.90

-0.2900-1.44%

盤後：19.900.00000.00%16:10 EDT

成交量：144.93萬

成交額：2,913.92萬

市值：12.28億

市盈率：-0.02

高：21.33

開：20.47

低：18.44

收：20.19

52周最高：49.97

52周最低：14.57

股本：6,172.72萬

流通股本：5,946.21萬

量比：25.28

換手率：2.44%

股息：- -

股息率：- -

每股收益(TTM):-1,287.1293

每股收益(LYR):-2,056.1834

淨資產收益率：--

總資產收益率：--

市淨率：-4.45

市盈率(LYR):-0.01

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Obsidian Therapeutics Inc

交易所：

NASDAQ

成立時間：

2015

員工人數：

71

公司地址：

1030 Massachusetts Avenue,Cambridge,Massachusetts,United States

官網：

http://www.obsidiantx.com

郵編：

02138

電話：

傳真：

- -

簡介：

Obsidian Therapeutics, Inc.是一家於2026年4月10日在特拉華州註冊成立的生物製藥公司。該公司專註於開發小分子超氧化物歧化酶（SOD）模擬物，旨在通過減少副作用來改善癌症放射治療的效果。Obsidian目前的產品組合包括一種泛NOS抑製劑，其主要研發項目正處於乳腺癌聯合治療的I/II期臨床試驗階段。該公司還開發用於治療實體瘤的工程化腫瘤浸潤淋巴細胞（TIL）療法。Obsidian的專有cytoDRiVE平台能夠通過藥物響應結構域控制蛋白質功能，初期重點開發基於該平台的TIL細胞療法。Obsidian的主要候選產品是一種新型的基因工程自體TIL細胞療法，目前正在進行治療晚期黑色素瘤和非小細胞肺癌的臨床試驗。

董事

名稱

職位

Madan Jagasia

Chief Executive Officer and Director

Maria Fardis

Chairman of the Board and Director

Heidi Hagen

Director

Matthew Norkunas

Director

Peter Barrett

Director

Robert Ross

Director

股東

名稱

職位

Madan Jagasia

Chief Executive Officer and Director

Julie Feder

Chief Financial Officer and Principal Accounting Officer

Dana Alexander

Chief Technical Officer

Parameswaran Hari

Chief Medical Officer

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/OBX/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OBX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OBX\",,,,,undefined,":{"symbol":"OBX","market":"US","secType":"STK","nameCN":"Obsidian Therapeutics Inc","latestPrice":19.9,"timestamp":1787342400000,"preClose":20.19,"halted":0,"volume":1449276,"hourTrading":{"tag":"盘后","latestPrice":19.9,"preClose":19.9,"latestTime":"16:10 EDT","volume":63,"amount":1260.38,"timestamp":1787343004329,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.014363546310054615,"floatShares":59462058,"shares":61727211,"eps":-1287.1293,"marketStatus":"未開盤","change":-0.29,"latestTime":"08-21 16:00:00 EDT","open":20.47,"high":21.33,"low":18.44,"amount":29139188,"amplitude":0.14314,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1287.1293,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":20.19,"preHourTrading":{"tag":"盘前","latestPrice":19.49,"preClose":20.19,"latestTime":"04:00 EDT","volume":1,"amount":19.49,"timestamp":1787299213996,"change":-0.7,"changeRate":-0.034671,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":19.9,"preClose":19.9,"latestTime":"16:10 EDT","volume":63,"amount":1260.38,"timestamp":1787343004329,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":25.277246844626724},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OBX\",,,,,undefined,":{"symbol":"OBX","floatShares":59462058,"roa":"--","roe":"--","lyrEps":-2056.183449,"volumeRatio":25.277246844626724,"shares":61727211,"dividePrice":0,"high":21.33,"amplitude":0.14314,"preClose":20.19,"low":18.44,"week52Low":14.57,"pbRate":"-4.45","week52High":49.9699,"institutionHeld":0,"latestPrice":19.9,"eps":-1287.1293,"divideRate":0,"volume":1449276,"delay":0,"ttmEps":-1287.1293,"open":20.47,"prevYearClose":49.9699,"prevWeekClose":17.77,"prevMonthClose":49.9699,"prevQuarterClose":49.9699,"fiveDayClose":17.77},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OBX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-04","symbol":"OBX","defaultRemindTime":1785850200000,"type":"split","dateTimestamp":1785816000000,"forFactor":10000,"toFactor":7019,"ratio":1.4247043738424277}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OBX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OBX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OBX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OBX","date":"2026-08-21","current":-0.015461,"percent":0.444444,"low":-15.919767,"twenty":-13.181567,"median":-9.14022,"eighty":-8.501155,"high":-7.975803,"avg":-10.814753,"sd":2.808659,"marketCap":874758582},"quantilePoints":[{"date":"2026-08-14","current":-8.605771,"twenty":-15.155618,"median":-12.735814,"eighty":-11.727865,"marketCap":819734144},{"date":"2026-08-21","current":-9.183431,"twenty":-13.181567,"median":-9.14022,"eighty":-8.501155,"marketCap":874758582}],"updateTime":1787533864793},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":374941308,"yearFounded":2015,"employeeNum":71,"address":"1030 Massachusetts Avenue,Cambridge,Massachusetts,United States","zipCode":"02138","officePhone":"(781) 806-6245","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"websiteUrl":"http://www.obsidiantx.com","stockEarnings":[{"period":"1week","weight":0.1199},{"period":"1month","weight":-0.6018},{"period":"ytd","weight":-0.6018}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.1107},{"period":"1year","weight":0.2048},{"period":"ytd","weight":0.1229}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Obsidian Therapeutics, Inc.是一家於2026年4月10日在特拉華州註冊成立的生物製藥公司。該公司專註於開發小分子超氧化物歧化酶（SOD）模擬物，旨在通過減少副作用來改善癌症放射治療的效果。Obsidian目前的產品組合包括一種泛NOS抑製劑，其主要研發項目正處於乳腺癌聯合治療的I/II期臨床試驗階段。該公司還開發用於治療實體瘤的工程化腫瘤浸潤淋巴細胞（TIL）療法。Obsidian的專有cytoDRiVE平台能夠通過藥物響應結構域控制蛋白質功能，初期重點開發基於該平台的TIL細胞療法。Obsidian的主要候選產品是一種新型的基因工程自體TIL細胞療法，目前正在進行治療晚期黑色素瘤和非小細胞肺癌的臨床試驗。","exchange":"NASDAQ","name":"Obsidian Therapeutics Inc","nameEN":"Obsidian Therapeutics Inc"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"OBX\",market:\"US\",,,undefined,":{"directors":[{"name":"Madan Jagasia","position":"Chief Executive Officer and Director"},{"name":"Maria Fardis","position":"Chairman of the Board and Director"},{"name":"Heidi Hagen","position":"Director"},{"name":"Matthew Norkunas","position":"Director"},{"name":"Peter Barrett","position":"Director"},{"name":"Robert Ross","position":"Director"}],"executives":[{"name":"Madan Jagasia","position":"Chief Executive Officer and Director"},{"name":"Julie Feder","position":"Chief Financial Officer and Principal Accounting Officer"},{"name":"Dana Alexander","position":"Chief Technical Officer"},{"name":"Parameswaran Hari","position":"Chief Medical Officer"}]}}}